Abstract: 5-aminosalicylic acid(5-ASA) is the primary drug candidate for the treatment of inflammatory bowel disease(IBD); However, its targeted efficacy in colon site is limited as majority of the drug is absorbed by small intestine after oral administration. As such, great interest is focusing on the design of colon-targeted drug delivery systems to deliver drugs at targeted site, thus enhancing therapeutic efficacy. This paper summarize recent progress in the development of colon-targeted drug delivery systems for 5-ASA, aiming at providing valuable information for IBD treatment.